Unmet Need Aqualung Therapeutics targets severe lung inflammation with limited FDA approved options, presenting a clear market need for innovative anti inflammatory therapies in VILI, IPF, and pulmonary hypertension—a strong pull for strategic partnerships and licensing discussions with larger biopharma seeking novel modalities.

NAMPT Target The company’s focus on NAMPT and the eNAMPT pathway via a humanized monoclonal antibody positions it as a differentiator in immun therapeutics, offering potential collaboration opportunities with firms pursuing targeted biologics and biomarker driven patient stratification.

Early Stage Funding With a funding base of around 22 million and a recent convertible note momentum, there are active investor relations and co development opportunities for partners open to milestone-driven collaborations and potential co financing.

Strategic Alliances Past licensing partnerships, such as with LeaderMed, indicate a openness to collaborations; sales outreach can explore license deals, co development, or regional partnerships to commercialize the ALT 100 mAb and NAMPT related platforms.

Thought Leader Presence Recent board appointment and industry recognition events signal a growing credibility; engaging with their leadership and leveraging AZ Bio and investor conference exposure can create pitch opportunities for strategic alliances and funding discussions.